Advertisement

PharmacoEconomics & Outcomes News

, Volume 817, Issue 1, pp 4–4 | Cite as

November 2018 news from ICER

News item
  • 4 Downloads

References

  1. 1.
    Institute for Clinical and Economic Review Report Finds Biologic Treatments for Uncontrolled Asthma Would Require More Than a 50% Price Discount to Reach Common Thresholds for Cost-Effectiveness.Internet Document: 13 November 2018. Available from: URL: https://icer-review.org/announcements/institute-for-clinical-and-economic-review-report-finds-biologic-treatments-for-uncontrolled-asthma-would-require-more-than-a-50-price-discount-to-reach-common-thresholds-for-cost-effectiveness/.Google Scholar
  2. 2.
    Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Issues Final Report on Long-Term Prophylaxis for Hereditary Angioedema, Provides Policy Recommendations to Improve Cost-Effectiveness. Internet Document : 15 Nov 2018. Available from: URL: https://icer-review.org/announcements/institute-for-clinical-and-economic-review-issues-final-report-on-long-term-prophylaxis-for-hereditary-angioedema-provides-policy-recommendations-to-improve-cost-effectiveness/.Google Scholar
  3. 3.
    Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Posts Draft Scoping Document for the Assessment of Treatments for Peanut Allergy. Internet Document : 20 Nov 2018. Available from: URL: https://icer-review.org/announcements/institute-for-clinical-and-economic-review-posts-draft-scoping-document-for-the-assessment-of-treatments-for-peanut-allergy/.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations